Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul-Sep;28(3):269-74.
doi: 10.1097/WAD.0000000000000029.

Community engagement in diverse populations for Alzheimer disease prevention trials

Affiliations

Community engagement in diverse populations for Alzheimer disease prevention trials

Heather R Romero et al. Alzheimer Dis Assoc Disord. 2014 Jul-Sep.

Abstract

The recruitment of asymptomatic volunteers has been identified as a critical factor that is delaying the development and validation of preventive therapies for Alzheimer disease (AD). Typical recruitment strategies involve the use of convenience samples or soliciting participation of older adults with a family history of AD from clinics and outreach efforts. However, high-risk groups, such as ethnic/racial minorities, are traditionally less likely to be recruited for AD prevention studies, thus limiting the ability to generalize findings for a significant proportion of the aging population. A community-engagement approach was used to create a registry of 2311 research-ready, healthy adult volunteers who reflect the ethnically diverse local community. Furthermore, the registry's actual commitment to research was examined, through demonstrated participation rates in a clinical study. The approach had varying levels of success in establishing a large, diverse pool of individuals who are interested in participating in pharmacological prevention trials and meet the criteria for primary prevention research trials designed to delay the onset of AD. Our efforts suggest that entry criteria for the clinical trials need to be carefully considered to be inclusive of African Americans, and that sustained effort is needed to engage African Americans in pharmacological prevention approaches.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of Participants and Timeline

References

    1. U.S. Department of Health & Human Services [Accessed November 1st, 2013];National plan to address alzheimer’s disease: 2013 update. http://aspe.hhs.gov/daltcp/napa/NatlPlan2013.shtml. Updated 2013.
    1. Khachaturian ZS, Barnes D, Einstein R, et al. Developing a national strategy to prevent dementia: Leon thal symposium 2009. Alzheimers & Dementia. 2010;6(2):89–97. - PMC - PubMed
    1. Meinert CL, Breitner JCS. Chronic disease long-term drug prevention trials: Lessons from the alzheimer’s disease anti-inflammatory prevention trial (ADAPT) Alzheimers & Dementia. 2008;4(1):S7–S14. - PubMed
    1. Neaton J, Grimm R, Cutler J. Recruitment of participants for the multiple risk factor intervention trial (mrfit) Control Clin Trials. 1987;8(4):S41–S53. - PubMed
    1. Reiman EM, Langbaum JBS, Fleisher AS, et al. Alzheimer’s prevention initiative: A plan to accelerate the evaluation of presymptomatic treatments. Journal of Alzheimers Disease. 2011;26:321–329. - PMC - PubMed

Publication types